

AMEDISYS INC  
Form 8-K  
October 06, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**  
**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): October 3, 2016**

**Commission File Number: 0-24260**

**Amedisys, Inc.**

**(Exact name of registrant as specified in charter)**

<b>(State or other jurisdiction of incorporation or organization)</b>	<b>(IRS Employer Identification No.)</b>
<b>3854 American Way, Suite A, Baton Rouge, LA 70816</b>	
<b>(Address of principal executive offices, including zip code)</b>	
<b>(225) 292-2031 or (800) 467-2662</b>	
<b>(Registrant's telephone number, including area code)</b>	
<b>(Former name or former address, if changed since last report)</b>	

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On October 3, 2016, Amedisys, Inc. (the Company) and Martin B. Howard, the Company's Chief Information Officer, mutually agreed that Mr. Howard will be leaving the Company effective as of October 31, 2016. Mr. Howard's departure from the Company will constitute a termination without cause. Michael North, the Company's Senior Vice President of Operations, who was responsible for the Company's conversion to Homecare Homebase (a leading platform for home health and hospice companies), will serve as the Company's Interim Chief Information Officer.

**Item 7.01. Regulation FD Disclosure.**

On October 6, 2016, the Company issued a press release announcing that Mr. Howard is leaving the Company, effective October 31, 2016, and that Mr. North will assume the role of Interim Chief Information Officer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release dated October 6, 2016

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC.

By: /s/ Paul B. Kusserow  
Paul B. Kusserow  
President and Chief Executive Officer

DATE: October 6, 2016

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release dated October 6, 2016